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Purpose: Mesenchymal stem cells (MSCs) are multipotent and give rise to distinct-
ly differentiated cells from all three germ layers. Neuronal differentiation of MSC 
has great potential for cellular therapy. We examined whether the cluster of mechani-
cally made, not neurosphere, could be differentiated into neuron-like cells by growth 
factors, such as epidermal growth factor (EGF), hepatocyte growth factor (HGF), 
and vascular endothelial growth factor (VEGF). Materials and Methods: BMSCs 
grown confluent were mechanically separated with cell scrapers and masses of sepa-
rated cells were cultured to form cluster BMSCs. As described here cluster of BM-
SCs were differentiated into neuron-like cells by EGF, HGF, and VEGF. Differenti-
ated cells were analyzed by means of phase-contrast inverted microscopy, reverse 
transcriptase-polymerase chain reaction (RT-PCR), immunofluorescence, and immu-
nocytochemistry to identify the expression of neural specific markers. Results: For 
the group with growth factors, the shapes of neuron-like cells was observable a week 
later, and two weeks later, most cells were similar in shape to neuron-like cells. Par-
ticularly, in the group with chemical addition, various shapes of filament structures 
were seen among the cells. These culture conditions induced MSCs to exhibit a neu-
ral cell phenotype, expressing several neuro-glial specific markers. Conclusion: 
bone marrow-derived mesenchymal stem cells (BMSCs) could be easily induced to 
form clusters using mechanical scraping, not neurospheres, which in turn could dif-
ferentiate further into neuron-like cells and might open an attractive possibility for 
clinical cell therapy for neurodegenerative diseases. In the future, we consider that 
neuron-like cells differentiated from clusters of BMSCs are needed to be compared 
and analyzed on a physiological and molecular biological level with preexisting neu-
ronal cells, and studies on the possibility of their transplantation and differentiation 
capability in animal models are further required.
Key Words:    Neuron-like cells, mesenchymal stem cell, epidermal growth factor, 
vascular endothelial growth factor, hepatocyte growth factor
INTRODUCTION
Since the late 19th century, several scientists have suggested the existence of non-Keum Seok Bae, et al.
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into a blood vessel in a bone marrow transplantation model.7 
Mezey, et al.8 also discovered that when bone marrow cells 
are injected into mouse peritoneum, these cells migrate to 
the brain and differentiate into neurons.
Recent studies also report that these marrow-derived mes-
enchymal cells have a capacity to differentiate into neurons 
in ex vivo surroundings. Sanchez-Ramos, et al.20 used retino-
ic acid and brain-derived neurotrophic factors to differentiate 
BMSCs into neural cells, including neurons and astrocytes. 
Woodbury, et al.21 determined that using antioxidants such as 
β-mercaptoethanol (BME), dimethyl sulfoxide (DMSO), and 
butylated hydroxyanisole (BHA), they differentiated mar-
row-derived mesenchymal cells into neurons. The result was 
that within a few hours, most MSCs (80%) transformed into 
neuron-like shapes and expressed neuron-specific markers.
In the studies mentioned above concerning the potential 
of BMSC differentiation into neuron-like cells, the results 
from these studies suggest that these MSCs can be applied 
to the treatment of various brain and nerve diseases. There-
fore, the goal of this study is to determine an effective meth-
od of differentiating BMSCs into neuron-like cells. We used 
EGF, vascular endothelial growth factor (VEGF), and hepa-
tocyte growth factor (HGF), and observed the conditions of 
differentiation.
EGF and VEGF are known to function as growth factors 
that stimulate proliferation of brain tissue-derived neural 
mesenchymal cells in culture.22-26 HGF is a heterodimer that 
consists of a chain containing four kringles and a serine 
protease-like b chain and is also called as scatter factor. It 
binds to c-Met, the tyrosine kinase receptor,27 and it is a 
growth factor that has pleiotrophic roles.28 Above all, within 
the neural tissue, tyrosine kinase receptor and its ligands are 
expressed, and they play an important role in survival, dif-
ferentiation and regeneration of neurons.
The ability of these cells to neurogenically differentiate 
has deep potential that is applicable to the field of cell ther-
apy. Nerve tissue has a limited ability to repair itself after 
injury.29-32 Generally, groups of cells suggested for neuro-
genic cell therapy are embryonic stem cells and neuron stem 
cells acquired in embryo or adult brain tissue.33-36 However, 
the use of these cells has limited application in clinical cir-
cumstances due to ethical and legal issues.
BMSCs and their ability to differentiate into neuron-like 
cells play an important role in the treatment of degenerative 
nerve diseases such as Parkinson’s disease, Huntington’s 
disease, and Amyotrophic Lateral sclerosis.37-39 It is being 
recognized that bone marrow that functions as storage for 
hematopoietic stem cells besides the most common stem 
cells of hematopoietic origin. In 1968, Friedenstein et al 
proved that these cells can be formed into bone, and in 
1985 Owen1 reported that cells with self renewal and multi-
differentiation capacity may be present in bone marrow on 
the basis of these cells’ similarity to hematopoietic cells. 
These have been named as bone marrow derived mesen-
chymal stem cells (MSCs), or marrow stromal stem cells, 
and there are many researches who focus their aims on 
these cells.
MSCs are harvested from fat, cord blood, and embryos as 
well as from bone marrow. They have the potential to dif-
ferentiate into marrow stromal cells, fat cells, osteoblastic 
cells, chondrocytes, tendinocytes, and myocytes, which are 
normally derived from mesenchymal stem cells.2-13 They 
are also capable of differentiating into endodermal origin 
hepatocytes and ectodermal origin neurons. Therefore, these 
differentiation potentials of MSCsare used for research into 
possible clinical utilization in regenerative cell therapy.
Generally, the number of MSCs in the bone marrow is 
small. There are about 2 to 5 cells present in every 1×106 
mononuclear cells. Normally, the human body is thought to 
have about 1×106 MSCs. However, they are relatively easi-
ly separated and grown in culture, and they have a great 
proliferation capability of a billion-fold increase in number 
ex vivo without losing their stem cell characteristics. Nota-
bly, Kuznetsov, et al.14 identified several growth factors that 
are related to MSCs. They reported that MSCs under the 
presence of serum, platelet derived growth factor (PDGF), 
basic fibroblast growth factor (bFGF), transforming growth 
factor β (TGF-β), and epidermal growth factor (EGF) can 
form in vitro colonies.15
The Ancient Chinese once said that the “brain is the sea 
of bone marrow.” These ancient beliefs are now being prov-
en one by one in recent times.16 Eglitis and Mezey17 report-
ed bone marrow derived cells discovered in the all brain 
parts from the cortex to the brain stem. Particularly, in the 
case of human MSCs, they migrate and survive similarly to 
mice astrocytes when grafted in mice striatum, and they are 
discovered to lose their marrow mesenchymal cell mark-
ers.18 When marrow-derived mesenchymal cells are trans-
planted into the lateral ventricles of a mouse, Kopen, et al.19 
discovered that the cells migrated to parts of forebrain and 
cerebellum, and some cells differentiated into atrocities and 
neurons containing neurofilaments. Along with this work, 
Brazelton, et al. determined that injected MSCs differentiat-
ed into neurons in the central nervous system when injected Neuronal Differentiation from Mesenchymal Stem Cell
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ROTEC), CD73-PE (BD), CD45-FITC (BD), CD34-FITC 
(BD), CD14-FITC (BD), and control (IgG1-FITC and 
IgG1-PE, BD)] for 45 min at room temperature. They were 
then washed three times with PBS and precipitated. The 
cells were dripped into columns and fixed with flow buffer 
(0.1% sodium azide, 1% paraformaldehyde, 0.5% bovine 
serum albumin). Finally, the cells were analyzed under Ep-
ics XL (Beckman Coulter, Brea, CA, USA). 
Differentiation capability test 
Osteogenic differentiation of BMSCs
BMSCs (second passage) in the early phase of culture were 
suspended to DMEM. They were divided into 24 well plates 
(5×104 cells/well) and cultured for 24 hours. Then, the me-
dium was replaced with osteoblast differentiation medium 
[High-glucose DMEM, 10% fetal bovine serum, 0.1 µM 
dexamethasone (Sigma, St. Louis, MO, USA), 10 mM 
β-glycerol phosphate, 50 µM L-ascorbic acid] and cultured 
for three weeks. The medium was replaced twice a week.
Chondrogenic differentiation of BMSCs
BMSCs were suspended in chondrogenic medium (6.25 
μg/mL insulin, 6.25 μg/mL transferrin, 6.25 μg/mL sele-
nous acid, 5.35 μg/mL linoleic acid, 1.25 μg/mL bovine se-
rum albumin), 1 mM Pyruvate, 37.5 μg/mL Ascorbic acid, 
10-7 M dexamethasone (Sigma)]. It was then centrifuged 
for 10 minutes in 450 xg. The precipitated cells were cul-
tured in chondrogenic medium for three weeks as micro-
mass. The medium was replaced for twice a week, and later 
stained to identify differentiation.
Adipogenic differentiation of BMSCs
BMSCs were suspended in DMEM, and divided into six 
well plates. These were cultured for 48 hours. The cultured 
cells were grown for three additional days under 100% den-
sity. Adipogenic induction medium [high glucose DMEM, 
10% fetal bovine serum, 1 μM dexamethasone (Sigma), 10 
ug/mL insulin (Sigma), 100 μM indomethacin (Sigma), and 
0.5 mM methyl-isobutylzanthine (Sigma)] was used for a 
72-hour culture and to induce differentiation. The medium 
was removed and replaced with adipogenic maintenance 
medium [high glucose DMEM, 10% fetal bovine serum, 10 
ug/mL insulin (Sigma)] to culture for 24 hours. The re-
placement of the media was repeated for three times. Then, 
finally, the sample was cultured for one additional week 
with adipogenic maintenance medium.
hematopoietic stem cells and MSCs can replace embryonic 
stem cells in protection and cell therapy of dying nerves.40-43 
In fact, acquiring autologous stem cells, inducing less pain in 
patients, proliferating stem cells in vitro, differentiating, 
and transplanting cells back into the same patient is a new 
concept, and has interesting possibility as a new treatment 
method. 
In this study, we used growth factors usually found in the 
human body to induce differentiation to neuron-like cells. 
We expect that this revolutionizing autologous cell therapy 
will be promising for the treatment of neurodegenerative 
diseases.
MATERIALS AND METHODS
Bone marrow collection and mesenchymal stem cell 
culture
Patients with no notable pathologic history were chosen for 
this study. Human bone marrow of three healthy donors aged 
21 to 40 years was obtained from Institute of cell therapy 
center before 2005, after they gave informed consent accord-
ing to the approved procedure. About 10 mL of marrow were 
collected from the pelvis of each patient and stored in a hepa-
rin containing test tube. 30 mL of phosphate buffered saline 
(PBS) was added to marrow sample. Then, the mixture was 
slowly streamed down on Ficoll-Plaque TM plus solution. 
The mixture was centrifuged using density gradient centrifu-
gation for 20 minutes in 2,000 rpm. Next, the top layer and 
monocyte layer present in the interface of Ficoll-Plaque TM 
plus were retrieved and mixed again with 20 mL of PBS. 
Again, the blend was centrifuged in 1,800 rpm for 5 minutes, 
and this time only the monocyte was retrieved.
The separated monocytes were placed in Dulbecco’s Mod-
ified Eagle’s Medium (DMEM, 10 % FBS, 1×penicillin-
streptomycin). Then, appropriate amounts of monocytes 
(2×105) were inoculated into a culture dish (T-75), and cul-
tured in an incubator.
After seven to ten days, since only MSCs in monocytes 
proliferated on the floor of the culture dish, the medium 
was replaced. Later, when MSCs proliferated over 80% of 
the culture dish, it was transferred to other culture dish (T-
175) for subculture. The medium was replaced once every 
three to four days to subculture 5 times.
Fluorescence Activated Cell Sorting (FACS) analysis
BMSCs were reacted with antibodies [CD105-FITC (SE-Keum Seok Bae, et al.
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ville, MD, USA), HGF, 20 ng/mL, (R&D Systems, Minne-
apolis, MN, USA), VEGF, 20 ng/mL, (R&D Systems), and 
was cultured with replacement of the medium at 3 day in-
tervals for 14 days. The group with chemicals was cultured 
with the DMEM medium for seven days, and on the eighth 
day, a chemical compound (BHA 200 µM, KCl 5 mM, Val-
proic acid 2 µM, Forskolin 10 µM, Hydrocortisone 1 µM, 
Insulin 5 µM) was added to the medium for an additional 
five days of culture.
Immunostaining 
Immunochemical staining
The differentiated cells were suspended on a cm2 cover 
slide at a 1×104 cells/cm2 concentration. After fixation, the 
slide was washed with PBS for 5 minutes and fixed with 
4% paraformaldehyde with PBS for 15 minutes. It was then 
washed twice with PBS for 5 minutes. Later, the sample 
was processed with PBS containing 1% BSA and 0.2% Tri-
ton X-100 for 5 minutes. Primary antibody was mixed and 
allowed to react for 16 hours. Anti-human neuron-specific 
enolase (NSE); Chemicon Inc., Billerica, MA, USA), anti-
human NeuN (Chemicon Inc.), anti-human β-tubulin III 
(Sigma Co., St. Louis, MO, USA), anti-human glial fibril-
lary acidic protein (GFAP); Sigma Co.), and anti-human 
microtubule-associated protein-2 (MAP-2) were used for 
primary antibodies. After the reaction with the primary anti-
body, PBS with 0.5% BSA was used to wash twice for 15 
minutes. The sample was cultured again with secondary an-
tibody for 30 minutes. PBS with 0.5% BSA was used to 
wash twice for 5 minutes. Afterward, the Avidin-biotin re-
action (Vectastain Elite ABC kit; Vector Laboratory Inc., 
Burlingame, CA, USA) was processed for 30 minutes. It 
was washed twice for 5 minutes with PBS. 3,3’-diamino-
benzidine tetrahydrochloride dehydrate (DAB, Sigma Co.) 
was mixed as a staining substrate and left to react for five 
minutes. Processing with PBS for five minutes stopped the 
reaction and it was further washed with PBS two more 
times. The sample was dried and then washed with distilled 
water for five minutes. Finally, it was washed and dehydrat-
ed with distilled water, 70%, 80%, 95%, and 100% ethanol 
(in that order), and suspended.
Immunofluorescence staining
For immunofluorescent staining, the cells were transferred 
to a culture slide (four-chamber, BD Falcon, Franklin 
Lakes, NJ, USA) and cultured for 1-2 days. Using 4% para-
Confirmation of differentiation capability
Alkaline phosphatase staining of osteoblasts
Alkaline phosphatase staining method was used to confirm 
the differentiation of BMSCs into osteoblasts. Cells that 
had been cultured in a 24-well plate for three weeks were 
removed from the media and washed twice with PBS. Ice-
cold methanol (99.9%) was added and fixed in room tem-
perature for two minutes. Then, it was washed with tertiary 
distilled water. BCIP/NBP (Sigma) liquid substrate was add-
ed and reacted with the sample for 10 minutes at an ambi-
ent temperature. Again, the mixture was washed twice with 
tertiary distilled water. The stain results were later analyzed 
under an optical microscope. 
Safranin O staining of chondrocytes
The cultured cells were suspended in ice-cold acetone for 
1-2 minutes after washing PBS. Mayer’s hematoxylin solu-
tion was used to stain for 10 minutes and washed with a 
bluing solution, and then with distilled water. 0.1% safranin 
O solution was added and allowed to react for five minutes. 
Every two minutes, the sample was added to the following 
solutions in order: 95% ethyl alcohol, absolute ethyl alco-
hol, and xylene. The sample was mounted on a slide and 
their differentiation was studied under a microscope.
Oil red-O staining of adipocytes
Lipid staining using oil red O was used to confirm the dif-
ferentiation of adipocytes from BMSCs. Cells that were 
cultured for 4 weeks in a six-well plate were mixed with 
4% paraformaldehyde (in PBS) and fixed for 4 to 12 hours. 
The sample was then washed with 60% isopropanol (in 
PBS). It was stained with a 60% oil red-O solution (in 
PBS) for 45 minutes and washed with distilled water. The 
sample was tested under an optical microscope.
Neuron-like cell differentiation
The study was divided into two groups. One group was treat-
ed with only growth factors, and the other was processed 
with chemicals. First, BMSCs were cultured to occupy the 
entire culture medium and separated with a cell scraper. 
Masses of separated MSCs were then cultured to form 1-2 
cluster/cm2. After 24 hours, when the BMSCs attached and 
started growing in the medium, growth factors and chemi-
cals were added as appropriate to each group of cells. Ini-
tially, for the group with growth factors only, the DMEM 
medium was added with EGF, 10 ng/mL, (Gibco BRL, Rock-Neuronal Differentiation from Mesenchymal Stem Cell
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10 minutes at 55- 60°C.
cDNA synthesis
The total RNA that had been separated was treated with DN-
ase. RNA 1 ug was added to Cyclescript RT preMix (dT20, 
Bioneer Inc.) and cycle in Table 1 was repeated for 15 times 
to synthesize cDNA.
PCR
Using each synthesized cDNA as a mold, PCR was per-
formed with the primers mentioned in Table 2. A total of 30 
cycles were repeated.
Electrophoresis
Electrophoresis was performed on the DNA fragments syn-
thesized by PCR using 1.5% agarose gel on 1X TAE buffer 
under 50 V. It was stained with ethidium bromide and ob-
served under a U.V. illuminator.
Western blotting
Using a cell scraper, the cells in the medium were separated 
after being washed twice with PBS. After being collected 
into a 1.5 mL tube, radioimmunoprecipitation assay(RIPA) 
buffer [1% triton X-100, 1% sodium deoxycholate, 50 mM 
NaCl2, 50 mM tris-HCl, 1 mM sodium vanadate, 2 mM 
phenylmethanesulfonylfluoride (PMSF)] was added to ob-
tain lysate. The protein sample was quantified with a protein 
assay solution, and was next added to 4× sampling buffer. 
The sample was boiled for five minutes. After electrophore-
sis, transfer buffer (25 mM Tris base, 0.2 M glycine, 20% 
methanol) was used to transfer for one hour under 30V us-
ing Immobilon membrane (Millipore). The sample was then 
treated with blocking buffer (5% skim milk, 1X TBS, 0.1% 
formaldehyde in PBS, cells were fixed for 4-8 hours and 
washed three times with PBS. The sample was then added 
to blocking solution (5% BSA in PBS) and left to react for 
1 hour. Primary antibody was allowed to react for one hour 
at 4°C. After washing with PBS three times, mounting so-
lution was added and covered with a cover glass. The cells 
were observed under a fluorescent microscope. To test for 
expression of antigens of neurons, immunofluorescent stain-
ing was performed using Neuronal Nuclei (NeuN, 1 : 100, 
Chemicon Inc.), GFAP (1 : 1,000, Chemicon Inc.), MAP-2 
(1 : 500, Chemicon Inc.), Neuron Specific Enolase (NSE, 1 : 
100, Chemicon Inc.), TH2 (1 : 1,000, Chemicon Inc.), Gal C 
(1 : 500, Chemicon Inc.) as monoclonal antibodies.
RT-PCR
Total RNA separation
Each cell from 175 mm culture dish was washed twice with 
PBS. Then, 1 mL of AccuZol (Bioneer Inc., Alameda, CA, 
USA) was added and cells were harvested into 1.5 mL cen-
trifuge tube using a cell scraper. After adding 200 µL of chlo-
roform and shaking vigorously for 15 seconds, the mixture 
was left in ice for five minutes. The mixture was next centri-
fuged for 15 minutes at 12,000 rpm at 4°C. After the super-
natant was transferred to a 1.5 mL tube, an equal amount of 
isopropyl alcohol was added, and the mixture was left at 
-20°C for 10 minutes. At 4°C the mixture was centrifuged 
again for 15 minutes at 12,000 rpm. The supernatant was re-
moved and was washed with 1 mL of 80% ethanol. The so-
lution was centrifuged once again for 10 minutes in 12,000 
rpm at 4°C, and the supernatant was removed. The ribonu-
cleic acid (RNA) pellet was dried at room temperature for 10 
to 20 minutes. It was dissolved into DEPC-water and left for 
Table 1. cDNA Synthesis
Step Reaction Temperature Time
Step 1 Primer annealing 37°C 30 sec
Step 2 cDNA synthesis 48°C    4 min
Step 3 Melting secondary structure & cDNA synthesis 55°C 30 sec
Table 2. Prime Sequence for PCR
Primer sequence
GFAP for: GTG GGC AGG TGG GAG CTT GAT TCT rev: CTG GGG CGG CCT GGT ATG ACA
NSE for: CCC ACT GAT CCT TCC CGA TAC AT rev: CCG ATC TGG TTG ACC TTG AGC A
Map2 for: CCA TTT GCA ACA GGA AGA CAC rev: CAG CTC AAA TGC TTT GCA ACT AT
NF-M  for: GAG CGC AAA GAC TAC CTG AAG A rev: CAG CGA TTT CTA TAT CCA GAG CC 
GAP 43 for: TTT CCC ACC CAC TAG CCC TCT TTC rev: ATA TTT TGG ACT CCT CAG ATG AAC G
PCR, polymerase chain reaction; GFAP, glial fibrillary acidic protein; NSE, neuron specific enolase; MAP2, microtubule-associated pro-
tein 2; NF-M, neurofilament-middle; GAP 43, growth associated protein 43.Keum Seok Bae, et al.
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RESULTS
Marrow collection and MSCs culture
After seven days of culturing marrow derived eukaryocytes 
in the medium, cell clusters were confirmed under a micro-
scope. The attached cells were forming typical mesenchy-
mal stem cell shapes (form of neuroglial cells in a pyramid 
shape with many processes). The primary subculture was 
completed 15 days later (Fig. 1).
FACS analysis
FACS analysis was performed to confirm bone marrow-de-
rived MSCs. Cells from the fourth subculture were collect-
ed and tested for SH2 and SH4 expressions, which are 
markers specific to mesenchymal stem cells. The test re-
sults were 99.8% positive in cell culture. The test was nega-
tive for antibodies (CD45, CD34, CD14), which are specif-
ic markers to hematopoietic stem cells, in the negative 
control group. Thus, it was confirmed that the sample of 
cells that had been grown consisted purely of mesenchymal 
stem cells, with no hematopoietic cells (Fig. 2).
Differentiation capability test
Alkaline phosphatase and silver nitrate staining of osteoblasts
When replaced with and cultured under high-glucose DMEM 
[10% fetal bovine serum, 0.1 µM dexamethasone (Sigma), 
10 mM β-glycerol phosphate, 50 µM L-ascorbic acid] for 
three weeks, the stain for alkaline phosphatase and silver 
nitrate was positive. This confirmed the possibility of mes-
enchymal stem cells’ differentiation to osteoblasts (Fig. 3).
Safranin O staininig of chondrogenic cells
After forming BMSCs into a micromass shape using a cen-
trifuge, the cells were cultured in chondrogenic medium for 
three weeks. As a result of Safranin O stain, differentiation 
into chondrocytes was observed (Fig. 4).
Oil red-O staining of adipocytes
After culturing with adipogenic induction medium, the re-
sult of Oil red-O staining showed and confirmed adipocyte 
differentiation (red fat vacuoles stained with Oil red-O in 
cells) (Fig. 5).
Differentiation into neuron-like cells
When cultured with the addition of growth factors or chem-
TWEEN 20, polyoxyethylene (20) sorbitan monolaurate) for 
one hour. At 4°C, antibody [GFAP, NSE, galactocerebroside 
(Gal C), and NeuN] was allowed to react for 12 hours. 
Then, washing buffer [1X TBS, 0.1% TWEEN 20, poly-
oxyethylene (20) sorbitan monolaurate)] was used three 
times for five minutes each. Horseradish peroxidase bound 
secondary antibody was added to the reaction for one hour. 
It was washed three times with washing buffer. The result 
was verified with enhanced chemiluminescence (ECL) sys-
tem (Habersham Bioscience).
Fig. 1. Mesenchymal stem cell culture (×100). (A) After 7 days of culturing. 
(B) After 14 days of culturing. (C) Subculture (4 times). (D) Cluster of BMSCs.
A
C
B
D
Fig. 3. Possibility of mesenchymal stem cells’ differentiation to osteoblasts 
(×100). (A) Alkaline phosphatese staining. (B) Silver nitrate staining. 
A B
Fig. 2. Fluorescence Activated Cell Sorting (FACS) analysis.
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with for two weeks. When the grown and proliferated cells 
were immunohistochemically tested for neurocyte markers 
such as NSE, NeuN, and GFAP, the number of positive cells 
for each stain was very small in the group that was treated with 
EGF alone. However, when treated with both EGF and HGF, 
cells that showed positive stains for each staining method were 
clearly observed. Based on the results mentioned above, the 
medium treated with both EGF and HGF was much higher in 
positive immunohistochemical stain ratio than the medium 
processed with EGF only when investigated regarding the im-
munohistochemical staining ratio that was positively stained in 
each condition (Table 3).
icals, each group showed that, as differentiation progressed, 
the cells’ processes became thinner and longer, similar to 
neurocytes, and morphologic changes were observed, such 
as the area of cytoplasm around the nucleus growing small-
er. For the group with growth factor, the shape of neuron-
like cells was observable a week later, and two weeks later, 
most of the cells were similar in shape to neurocytes. Particu-
larly, in the group with chemical additions, filament struc-
tures of various shapes were seen among the cells (Fig. 6).
Next, to compare and to observe the effects of growth fac-
tors used in differentiation into neuron-like cells, EGF alone or 
a combination of EGF and HGF was given, to be followed up 
Fig. 5. Oil red-O staining of adipocytes. MSC, mesenchymal stem cell.
Control MSCs Adipocytes
Table 3. Immunohistochemically Tested for Neurocyte Markers
NSE NeuN GFAP
EGF 0.9 % 0.8 % 1.2 %
EGF and HGF 56 % 75 %  24 %
GFAP, glial fibrillary acidic protein; NSE, neuron specific enolase; NeuN, neuronal nuclei; EGF, epidermal growth factor; HGF, hepatocyte 
growth factor.
Control 1 wk
TGF 1 wk
Control 2 wk
TGF 2 wk
Control 3 wk
TGF 3 wk
Fig. 4. Cultured cells in chondrogenic medium for 3 weeks (×100). TGF, tumor growth factor.
Fig. 6. Differentiation into bone marrow-derived neuron-like cells (×200). (A) Mesenchymal stem cells. (B) Growth factor group (1 week). 
(C) Growth factor group (2 weeks). (D) Chemical group (2 weeks).
A B C DKeum Seok Bae, et al.
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godendrocyte was a strong posititve only in the group with 
growth factors. Through these results, we discovered that 
MSCs are capable of differentiating into neurocytes and 
glial cells; in addition, we could also confirm the differenti-
ation of part of MSCs population into oligodendrocytes 
(Fig. 8). 
RT-PCR
Although all the groups showed expression of the gene in 
the case of GFAP, the group with growth factor only showed 
increased expression of the gene. For NSE, the control group 
was expressed minutely. NSE was much more highly ex-
pressed in the group with growth factor only. The group 
treated with chemicals also showed higher expression than 
the control group, but less than the group treated with growth 
factor. It was discovered that MAP2, NF-M, and GAP43 
were only expressed in the group with chemical mediators. 
Based on these results, according to particular differentia-
tion conditions, specific markers of some neuron-like cells 
show differences in expression level (Fig. 9).
Immunostaining
Immunochemical staining
For the group treated with growth factors for two weeks, im-
munohistochemical staining of each neurocyte-specific mark-
er (NSE, NeuN, and GFAP) was performed. It was confirmed 
that all the markers were positively stained. Namely, it was 
verified that inducing MSCs differentiation into neuron-like 
cells by growth factors caused the cells to differentiate most-
ly to neurocytes and glial cells (Fig. 7).
Immunofluorescence staining
In the case of immunofluorescent staining in glial fibrillary 
acidic protein (GFAP), the group treated with growth fac-
tors for two weeks showed positive results. In the case of 
NeuN, the group with growth factors also resulted in posi-
tive reactions and even the staining of the control group 
showed weakly fluorescent results. In the case of Microtu-
bule-associated protein 2 (MAP2), the group with growth 
factors was a strong positive. Gal C  that is a marker of oli-
Fig. 8. Immunofluorescence staining (×200). (A and B) GFAP, glial fibrillary acidic protein. (C and D) NeuN, neuronal nuclei. (E and F) 
MAP2, microtubule-associated protein 2. (G and H) Gal C, galactocerebroside.
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Fig. 7. Immunochemical staining (×200). (A) NSE, neuron specific enolase. (B) NeuN, neuronal nuclei. (C) GFAP, glial fibrillary acidic protein.
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BMSCs using growth factors such as EGF, VEGF, and HGF, 
we can presume the following three possibilities.
First, there exists a neurocyte subpopulation that can be 
differentiated into neurocytes in BMSCs that are proliferat-
ed and cultured ex vivo. Second, BMSCs can be trans-dif-
ferentiated using a method such as mesenchymal epithelial 
transformation (MET). Finally, as we already know from 
the results of the RT-PCR and western blotting, under par-
ticular conditions of differentiation, it is possible to for cells 
to differentiate into neuron-like cells, each with different 
characteristics.
Bossolasco, et al.44 postulated that, since nestin and beta 
tubulin III, together with O4 and GFAP showed a positive 
reaction, MSCs already have a subpopulation that has a ca-
pability to differentiate into neuron-like cells. In addition, Ji-
ang, et al.45 reported that selectively proliferated cells can be 
differentiated into multipotent precursor cells with the char-
acteristic shapes of neurocytes, astrocytes, and oligodendro-
cytes. Chamberlain, et al.46 also proved the possible trans-
differentiation of mesenchymal stem cells.
Western blotting
With the exception of the control group, all the groups in-
duced differentiation showed expression of the protein GFAP. 
The group with growth factor showed markedly higher ex-
pression of protein than the group with chemicals. For 
NSE, the entire group showed expression of the protein, 
and the expression was particularly higher in the group 
with growth factor. In the Gal C test, the control group re-
sults were weakly positive for Gal C expression, and higher 
than the expression found in the group with chemicals. 
NeuN was expressed in high quantity in both groups with 
growth factor and with chemicals. Based on these results, 
according to particular differentiation conditions, specific 
markers of some neuron-like cells show a difference in the 
level of expression (Fig. 10).
DISCUSSION
Through the results of neuron-like cell differentiation from 
GFAP
NSE
Gal C
NeuN
Control group Growth factors 
1 week group
Growth factors 
2 week group Chemical group
Fig. 10. Western blotting. GFAP, glial fibrillary acidic protein; NSE, neuron specific enolase; NeuN, neuronal nuclei; Gal C, galactocerebroside.
GFAP
NSE
MAP2
NF-M
GAP 43
Control group Chemical group Growth factors 
1 week group
Growth factors 
2 week group
Fig. 9. Reverse transcriptase-Polymerase Chain Reaction. GFAP, glial fibrillary acidic protein; NSE, Neuron Specific Enolase; MAP2, 
Microtubule-associated protein 2; NF-M, Neurofilament-Middle; GAP 43, Growth Associated Protein 43.Keum Seok Bae, et al.
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mal cerebral infarct models, symptoms has resulted in re-
covery and decreased neurological deficit when injected 
with MSCs.8,61-63 It has also been discovered that when BM-
SCs are injected into blood vessels, rather than directly into 
damaged brain tissue, the cells have shown an ability to 
pass through the blood-brain barrier and to migrate to the 
damaged part of the brain.2,20,21,61,64 In a clinical study, Bang, 
et al.65 proliferated and introduced autologous MSCs intra-
venously to patients with cerebral infarction. They reported 
that injecting these stem cells had the effect of improving 
neurological symptoms, such as reducing the size of the in-
farct and decreasing the atrophy of the ventricle.66
In this study, BMSCs’ ability to proliferate and differenti-
ate into neuron-like cells by has indicated a possibility for 
application to cell therapy for a wide range of diseases such 
as neurodegenerative disease and cerebral infarct. Previous-
ly known methods of inducing neuron-like cell differentia-
tion using several chemicals have limits because the toxici-
ty of these chemicals makes them too risky to be applied in 
humans. However, the EGF, VEGF, and HGF used in this 
study are secreted in human body, and can be safely manip-
ulated to induce differentiation. Furthermore, the use of dif-
ferentiated neuron-like cells in clinical therapeutic methods 
may have fewer limitations. These cells also have autolo-
gous marrow origin, and are thus  free from severe compli-
cations; for example, immune rejection reaction. Because 
large quantities of neuron-like cells can be acquired from a 
small amount of bone marrow, these cells’ application in 
clinical therapy will be very useful.
In the future, it will be necessary to compare and analyze 
the characteristics of neuron-like cells originating from 
MSCs with other neurons in molecular biological and phys-
iological aspects. Further studies are required to uncover the 
possibilities of transplanting them into humans and differen-
tiating the cells within animal. 
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